VTGN
VistaGen Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.24
−1.38%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$10.77M
MomentumView details →
1D Return
−1.38%
YTD Return
−62.14%
RSI (14)
44.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$10.77M
RSI (14)
44.1
MomentumView details →
1D Return
−1.38%
YTD Return
−62.14%
SummaryUpdated Jun 1, 2026
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company founded in 1998 and headquartered in South San Francisco, California. The company specializes in developing novel treatments for central nervous system disorders, particularly anxiety and depression. VistaGen went public in 2011 and has built a pipeline of innovative nasal spray therapies that target brain neurocircuitry through a unique nose-to-brain delivery mechanism. The company is currently advancing multiple drug candidates through clinical trials, with its lead program for social anxiety disorder in Phase III development.
Similar companies
Latest newsMore news →
Vistagen Therapeutics reported Q1 FY2027 revenue of $1.476 million, up 504.9% year-over-year, with a net loss of $13.03 million and diluted EPS of -$0.30.22d agoVistagen announced topline results from its exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder, showing favorable safety and efficacy signals.29d agoVistagen Inc. reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for social anxiety disorder did not meet its primary endpoint in the overall study population.66d ago